Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04466280

Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19

Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19 Disease in Healthcare Providers at Baqiyatallah Hospital in Tehran

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Baqiyatallah Medical Sciences University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

180 people from the medical staff and high-risk people in Baqiyatallah Hospital, who are in close contact with patients, will enter the study. Participants will be divided into two intervention groups and one control group. The control group will use the full protective equipment assigned to the treatment staff. In addition to protective equipment, the first intervention team will receive a daily diet of 200 mg hydroxychloroquine tablets. The second intervention team, while observing and using the complete protective equipment, will place a thin layer of Mucodentol gel in the vestibular area of the mouth daily, every 6 to 8 hours. At the beginning of the treatment, qualified people will participate in the study while recording demographic and clinical information, PCR test will be performed, and if they have negative PCR, they will be in one of the 3 study groups. During the study, if the symptoms of the disease occur in each of the participants, the test will be taken again. If the test is positive, the person will withdraw from the study, and the patient's information will be recorded. Finally, the people present in the study will be tested for PCR, and the results of the disease and the side effects of the drugs will be compared.

Conditions

Interventions

TypeNameDescription
DRUGHydroxychloroquine200 mg of hydroxychloroquine daily for participants in the intervention group 1
DRUGMucodentolIntervention Group 2 participants will place a thin layer of Dentol gel in the vestibular area of the mouth every 6 to 8 hours.
DEVICEPersonal protective equipmentPersonal protective equipment such as masks, gloves, protective shields

Timeline

Start date
2020-08-12
Primary completion
2020-09-21
Completion
2020-09-21
First posted
2020-07-10
Last updated
2022-08-03

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT04466280. Inclusion in this directory is not an endorsement.

Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVI (NCT04466280) · Clinical Trials Directory